Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Suzanne Smith

Addiction Medicine Greenfield, MA Medical Doctor

NPI 1346521622 CMS profile 197326

489 Bernardston Rd Ste 108, Greenfield, MA 01301

Open in the dashboard

General payments

$118

6 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Suzanne Smith of Greenfield, MA is reported in the CMS Open Payments database as having received $118 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $36 2
2022 General $21 1
2021 General $43 2
2020 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzanne Smith
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Suzanne Smith were reported at $0. Among 183 Addiction Medicine profiles paid that year, the median was $124 and the middle half received between $43 and $384.

Show as a table
Year Suzanne Smith Addiction Medicine median Middle half National median
2019 $0 $115 $34–$328 $163
2020 $17 $64 $22–$259 $114
2021 $43 $97 $25–$267 $132
2022 $21 $70 $25–$255 $149
2023 $36 $105 $29–$270 $160
2024 $0 $122 $39–$378 $164
2025 $0 $124 $43–$384 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Gilead Sciences, Inc. $36 2 payments
  2. AbbVie, Inc. $22 1 payment
  3. Hikma Pharmaceuticals USA $21 1 payment
  4. Alkermes, Inc. $21 1 payment
  5. Indivior Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $97 5 payments
  2. Education $21 1 payment
Products named General payments · program years 2020–2023
  1. MAVYRET $22 1 payment
  2. Kloxxado $21 1 payment
  3. VIVITROL $21 1 payment
  4. SUBLOCADE $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

200

Median for Preventive Medicine: 100

Drug cost

$16,469

Median for Preventive Medicine: $5,055

Branded share of claims

71.5%

Median for Preventive Medicine: 27.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 113 $13,746
Buprenorphine Hcl Generic 24 $1,124
Methylphenidate Hcl Generic 20 $750
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 13 $428
Bupropion Xl Bupropion Hcl Brand 17 $254
Quetiapine Fumarate Generic 13 $166

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$171,493

Medicare's payments for the services billed

Medicare patients

209

Average age 54

Services billed

2,247

97 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 52%
High blood pressure 38%
Arthritis 29%
COPD 20%
Diabetes 16%
Ischemic heart disease 10%
Chronic kidney disease 9%
Atrial fibrillation 6%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record